Drug Royalty Company Profile

15:34 EST 22nd November 2017 | BioPortfolio

Drug Royalty is an innovative and profitable Canadian company involved in the international life science industry. Established in 1992, DRC was designed to participate in the growth from the global healthcare industry by investing in royalty streams generated from pharmaceutical products.


8 King Street East, Suite 202
M5C 1B5


Phone: (416) 863 1865
Fax: (416) 863 5161

News Articles [691 Associated News Articles listed on BioPortfolio]

Coming In Tuesday's "The Pink Sheet" DAILY - Royalty Pharma Makes A Move For Elan

Royalty Pharma’s $11 per-share bid for Elan is too low, according to Elan’s management and industry analysts.

News Headlines, PTV News: Apr 20, 2010

Forthcoming news stories – global drug sales “set to reach a trillion dollars” by 2014; Royalty Rate Report 2010 - the vital importance of getting the right deal; and Novartis reports first qua...

PharmaVentures: Valuation methods and trends in licensing deals

In this informative panel discussion, Fintan Walton talks with 3 members of PharmaVentures’ deal advisory team about Royalty Rates, particularly the valuation of deals in the pharmaceutical and biot...

Xynomic In-Licenses RAF Inhibitor from Boehringer in $502 Million Deal

Xynomic Pharma, a US-Shanghai clinical-stage oncology drug developer, acquired exclusive global rights to a 2nd-generation RAF inhibitor from Boehringer Ingelheim. Xynomic, which hopes BI 882370 will ...

PDL BioPharma (PDLI) - Depomed paying off

Edison Investment Research - Pharmaceutical & healthcare - PDL BioPharma: PDL BioPharma recently reported strong Q217 earnings mainly due to royalties related to the authorized generic of Glumetza as ...

Pfizer licenses 4 drug candidates to biotech startup

Pfizer is giving milestone- and royalty-bearing licenses for four compounds to its biotech startup SpringWorks Therapeutics a -More- 

Zealand reports royalty revenue for the third quarter of 2017

Company announcement - No. 49/2017  Zealand reports royalty revenue for the third quarter of 2017 Zealand reports royalty revenue of DKK 10.3 million/USD 1.6 million for Q3 2017 Th...

Biogen decreases aducanumab royalty obligations to Neurimmune

Drugs and Medications [0 Results]


PubMed Articles [2166 Associated PubMed Articles listed on BioPortfolio]

Invited Commentary. The Royalty of Evidence: The Randomized Control Trials.

Preferences of Patients and Pharmacists with Regard to the Management of Drug-Drug Interactions: A Choice-Based Conjoint Analysis.

The management of drug-drug interactions (DDIs) is a complex process in which risk-benefit assessments should be combined with the patient's perspective.

Trends in reports of driving following illicit drug consumption among regular drug users in Australia, 2007-2013: Has random roadside drug testing had a deterrent effect?

Driving following illicit drug consumption ('drug-driving') is a potential road safety risk. Roadside drug testing (RDT) is conducted across Australia with the dual aims of prosecuting drivers with dr...

Drug use generations and patterns of injection drug use: Birth cohort differences among people who inject drugs in Los Angeles and San Francisco, California.

A robust literature documents generational trends in drug use. We examined the implications of changing national drug use patterns on drug injection histories of diverse people who inject drugs (PWID)...

Drug cue reactivity involves hierarchical instrumental learning: evidence from a biconditional Pavlovian to instrumental transfer task.

Drug cue reactivity plays a crucial role in addiction, yet the underlying mechanisms are poorly understood. According to the binary associative account, drug stimuli retrieve an expectation of the dru...

Clinical Trials [1902 Associated Clinical Trials listed on BioPortfolio]

Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens

The joint status (knees, ankles) of patients suffering from severe Hemophilia A (too little blood clotting factor VIII in blood) is evaluated in a single magnetic resonance imaging session...

To Develop a Validated Program and Use it to Evaluate Patients Post-operatively

Annually, the Department of Anesthesiology, Siriraj hospital has responsibilities to take care of more than 50,000 patients peri-operatively. According to Maslow's hierarchy of needs; huma...

Intra-patient Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT (Optical Coherence Tomography) Follow up

The objective of the study is to evaluate the process of early re-endothelialization of the Coroflex® ISAR Drug-eluting stent compared with the Ultimaster® Drug-eluting stent

Basel Stent Kosten Effektivitäts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions

The investigators hypothesize that in a real-world population undergoing percutaneous coronary intervention (PCI) for de-novo stenoses in small native vessels with a diameter

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

The purpose of this study is to determine the safety of AZX100 Drug Product and to determine whether it is effective in preventing or reducing re-growth of surgically removed keloid scars.

Companies [1254 Associated Companies listed on BioPortfolio]


A pioneer in the field when launched in 1992, Drug Royalty was the first firm to provide royalty-based financing in the life sciences sector and the first to complete royalty transactions with invento...

Drug Royalty

Drug Royalty is an innovative and profitable Canadian company involved in the international life science industry. Established in 1992, DRC was designed to participate in the growth from the global he...

DRI Capital Inc.

DRI is a pioneer and global leader in healthcare royalty investing and has completed transactions with large global pharmaceutical companies, biotechnology companies, universities...

Capital Royalty L.P.

Our diversified team of investment professionals is dedicated to meeting the specific needs of each client, and with our extensive experience in the healthcare and financial industries, Capital Royalt...

Cowen Healthcare Royalty Partners

Cowen Healthcare Royalty Partners is a global healthcare private equity firm that invests principally in commercial-stage biopharmaceutical and medical device companies and products, through the purch...

More Information about "Drug Royalty" on BioPortfolio

We have published hundreds of Drug Royalty news stories on BioPortfolio along with dozens of Drug Royalty Clinical Trials and PubMed Articles about Drug Royalty for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Drug Royalty Companies in our database. You can also find out about relevant Drug Royalty Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Corporate Database Quicklinks

Searches Linking to this Company Record